The effective management of low-density lipoprotein cholesterol (LDL-C) after acute myocardial infarction (AMI) is a cornerstone of secondary prevention in contemporary cardiovascular care [1–5]. Extensive evidence has demonstrated that lowering LDL-C levels through effective lipid-lowering therapy (LLT) substantially reduces the risk of major cardiovascular events, with a proportional benefit for each mmol/L of LDL-C reduction [6–8]. Current European and American guidelines recommend a treatment goal of LDL-C < 55 mg/dL for very high-risk patients – such as individuals with AMI – and emphasize the need for combination therapy including ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and bempedoic acid, when statins alone are insufficient to achieve target levels [1–5].
